This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- beta-Sitosterol
- DrugBank Accession Number
- DB14038
- Background
Active fraction of Solanum trilobatum; reduces side-effects of radiation-induced toxicity.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for beta-Sitosterol (DB14038)
- Weight
- Average: 414.718
Monoisotopic: 414.38616623 - Chemical Formula
- C29H50O
- Synonyms
- (-)-β-Sitosterol
- (24R)-Ethylcholest-5-en-3beta-ol
- (24R)-ethylcholest-5-en-3β-ol
- (24R)-Stigmast-5-en-3beta-ol
- (3β)-Stigmast-5-en-3-ol
- 22,23-Dihydrostigmasterol
- 24α-Ethylcholesterol
- Azuprostat
- Cupreol
- Nimbosterol
- Sitosterol
- Triastonal
- α-Dihydrofucosterol
- β-Sitosterin
- External IDs
- SKF 14463
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Harzol
- Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Insadol Tablet 35 mg/1 Oral I World Pharmaceutical Co., Ltd. 2019-10-08 Not applicable US 
Insadol Tablet 35 mg/1 Oral LYDIA Co., Ltd 2019-10-08 Not applicable US Insadol Tablet 35 mg/1 Oral OASIS TRADING 2018-11-20 Not applicable US มีโบ Ointment 0.25 %w/w Topical บริษัท มีโบ จำกัด 1999-04-08 Not applicable Thailand 
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Insadol beta-Sitosterol (35 mg/1) Tablet Oral LYDIA Co., Ltd 2019-10-08 Not applicable US Insadol beta-Sitosterol (35 mg/1) Tablet Oral OASIS TRADING 2018-11-20 Not applicable US Insadol beta-Sitosterol (35 mg/1) Tablet Oral I World Pharmaceutical Co., Ltd. 2019-10-08 Not applicable US Mi-Omega NF beta-Sitosterol (200 mg/1) + Cyanocobalamin (500 ug/1) + Folic acid (1 mg/1) + Omega-3-acid ethyl esters (500 mg/1) + Pyridoxine hydrochloride (12.5 mg/1) Capsule Oral Mayne Pharma 2009-01-01 2016-05-31 US
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as stigmastanes and derivatives. These are sterol lipids with a structure based on the stigmastane skeleton, which consists of a cholestane moiety bearing an ethyl group at the carbon atom C24.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Stigmastanes and derivatives
- Direct Parent
- Stigmastanes and derivatives
- Alternative Parents
- Triterpenoids / C24-propyl sterols and derivatives / 3-beta-hydroxysteroids / 3-beta-hydroxy delta-5-steroids / Delta-5-steroids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
- Substituents
- 3-beta-hydroxy-delta-5-steroid / 3-beta-hydroxysteroid / 3-hydroxy-delta-5-steroid / 3-hydroxysteroid / Alcohol / Aliphatic homopolycyclic compound / C24-propyl-sterol-skeleton / Cyclic alcohol / Delta-5-steroid / Hydrocarbon derivative
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 3beta-sterol, phytosterols (CHEBI:27693) / stigmastane, Stigmasterols and C24-ethyl derivatives (C01753) / Stigmasterols and C24-ethyl derivatives (LMST01040129)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S347WMO6M4
- CAS number
- 83-46-5
- InChI Key
- KZJWDPNRJALLNS-VJSFXXLFSA-N
- InChI
- InChI=1S/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1
- IUPAC Name
- (1R,3aS,3bS,7S,9aR,9bS,11aR)-1-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-9a,11a-dimethyl-1H,2H,3H,3aH,3bH,4H,6H,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-ol
- SMILES
- [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC=C4C[C@@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CC[C@@H](CC)C(C)C
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000852
- KEGG Drug
- D08518
- KEGG Compound
- C01753
- ChemSpider
- 192962
- BindingDB
- 50218197
- 47070
- ChEBI
- 27693
- ChEMBL
- CHEMBL221542
- ZINC
- ZINC000004095717
- Wikipedia
- Beta-Sitosterol
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Chronic Periodontitis (Disorder) 1 1, 2 Unknown Status Treatment Graft Pain / Recession, Gingival 1 Not Available Completed Basic Science High Cholesterol / Indication for Carotid Endarterectomy / Symptomatic Carotid Stenosis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral 35 mg/1 Capsule Oral Capsule, coated Oral Capsule, gelatin coated Oral Ointment Topical 0.25 %w/w - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.84e-05 mg/mL ALOGPS logP 7.27 ALOGPS logP 7.84 Chemaxon logS -7.4 ALOGPS pKa (Strongest Acidic) 18.2 Chemaxon pKa (Strongest Basic) -1.4 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 20.23 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 129.77 m3·mol-1 Chemaxon Polarizability 54.21 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at May 17, 2018 20:50 / Updated at June 12, 2020 16:53